{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-073586","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.363483+00:00","generated_at":"2026-06-10T23:57:22.238885+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intensity Therapeutics presents updated INT230-6 data: Phase 3 sarcoma trial planned; tumor necrosis in breast cancer","bullets":["INT230-6 induced up to 95% tumor necrosis in presurgical breast cancer after 1-2 injections; safety profile favorable.","Phase 3 soft tissue sarcoma trial designed; median OS not reached vs synthetic control median of 205 days.","Phase 1/2 IT-01 study in 110 patients with 25 tumor types completed; database locked; data presented at ASCO and SITC.","Phase 2/3 breast cancer study designed; data expected Q4 2023; accelerated approval path via pCR discussed with FDA.","Company to present at H.C. Wainwright conference on Sept 11, 2023; one-on-one meetings available."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-073586","json":"https://secwatch.observer/filing/0001213900-23-073586.json","markdown":"https://secwatch.observer/filing/0001213900-23-073586.md","text":"https://secwatch.observer/filing/0001213900-23-073586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023073586/0001213900-23-073586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023073586/ea184623-8k_intensity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:57:22.238885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}